Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Farewell Message from the Retiring Editor-in-Chief.

Journal of insurance medicine (New York, N.Y.)·2024
Same author

Inside "Operation Change Agent": Mallinckrodt's Plan for Capturing the Opioid Market.

Journal of health politics, policy and law·2024
Same author

The opioid industry document archive: New directions in research on corporate political strategy.

The International journal on drug policy·2023
Same author

Attitudes towards the 'Shisha No Thanks' campaign video: Content analysis of Facebook comments.

Tobacco induced diseases·2022
Same author

Evaluation of 'Shisha No Thanks' - a co-design social marketing campaign on the harms of waterpipe smoking.

BMC public health·2022
Same author

Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scale.

Journal of patient-reported outcomes·2021

Related Experiment Video

Updated: Jul 7, 2026

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics
04:33

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

Published on: December 8, 2023

Natriuretic peptide testing--ready for insurance screening?

Ross MacKenzie

    Journal of Insurance Medicine (New York, N.Y.)
    |February 7, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Nitropeptide Profiling and Identification Illustrated by Angiotensin II
    07:31

    Nitropeptide Profiling and Identification Illustrated by Angiotensin II

    Published on: June 16, 2019

    Related Experiment Videos

    Last Updated: Jul 7, 2026

    CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics
    04:33

    CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

    Published on: December 8, 2023

    Nitropeptide Profiling and Identification Illustrated by Angiotensin II
    07:31

    Nitropeptide Profiling and Identification Illustrated by Angiotensin II

    Published on: June 16, 2019